<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328171</url>
  </required_header>
  <id_info>
    <org_study_id>AIO KRK 0109</org_study_id>
    <secondary_id>2009-017731-17</secondary_id>
    <nct_id>NCT01328171</nct_id>
  </id_info>
  <brief_title>FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)</brief_title>
  <acronym>VOLFI</acronym>
  <official_title>An Open-label 2:1 Randomized Phase II Study of Panitumumab Plus FOLFOXIRI or FOLFOXIRI Alone as First-line Treatment of Patients With Non-resectable Metastatic Colorectal Cancer and RAS Wild Type</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to optimize response rates and rates of secondary resections of
      metastases in patients with initially non-resectable metastatic colorectal cancer of RAS
      wildtype. The patients will be treated in two therapy groups:

      Experimental arm A: Chemotherapy with FOLFOXIRI + panitumumab Standard arm B: Chemotherapy
      with FOLFOXIRI
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>up to about 6 month</time_frame>
    <description>RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate in each cohort</measure>
    <time_frame>up to about 6 month</time_frame>
    <description>RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary resection rate with curative intent for patients cohort I</measure>
    <time_frame>up to about 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological response in liver surgery specimen</measure>
    <time_frame>up to about 6 month</time_frame>
    <description>metrics: Pathological complete response (pCR): no residual cancer cells;major response (pPR): 1% to 49% residual cancer cells remaining; minor response (pMR): 50% to 99% residual cancer cells remaining; no response (pNR): 100% residual cancer cells remaining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>up to about 6 month</time_frame>
    <description>CR + PR + SD rate according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 4 years</time_frame>
    <description>analyzed for responders only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>up to about 6 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause assessed up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to recurrence (cohort II in case of secondary resection)</measure>
    <time_frame>up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity and feasibility</measure>
    <time_frame>up to about 6 month</time_frame>
    <description>number of patients with adverse events and severity according to NCI CTC 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver toxicity for resected patients (central histological review); biopsies should be obtained for all patients pre-treatment</measure>
    <time_frame>up to 1 year</time_frame>
    <description>histological findings according to CASH/SOS scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QL (QLQ C30)</measure>
    <time_frame>Pre-treatment, before start of every 3rd cycle and at the end of treatment</time_frame>
    <description>scores according to EORTC QLQ-C30 scoring manual (Quality of life)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>translational research (EGFR genetics and proteomics): prognostic and predictive impact on efficacy outcomes</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Determination of EGFR mutations (exons 18, 19, 20, 21) in tumor tissue; determination of PIK3CA mutations (exon 9, 20) in tumor tissue; determination of EGFR, ERCC1, TS, MTHFR, OPRT, DHFR and CDKN polymorphism from normal and tumor tissue; determination of ERCC1, PTEN and TS protein expression in tumor tissue; epigenetic candidates; further exploratory studies such as miRNA analysis as approved by the AIO review board</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>A (FOLFOXIRI + Panitumumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOXIRI + Panitumumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B (FOLFOXIRI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOXIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI + Panitumumab</intervention_name>
    <description>irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles</description>
    <arm_group_label>A (FOLFOXIRI + Panitumumab)</arm_group_label>
    <other_name>Vectibix (Panitumumab)</other_name>
    <other_name>folic acid</other_name>
    <other_name>5-FU</other_name>
    <other_name>oxaliplatin</other_name>
    <other_name>irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles</description>
    <arm_group_label>B (FOLFOXIRI)</arm_group_label>
    <other_name>folic acid</other_name>
    <other_name>5-FU</other_name>
    <other_name>oxaliplatin</other_name>
    <other_name>irinotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cohort I: Histologically confirmed and definitively inoperable or irresectable
             metastatic colorectal cancer. Focus on patients with large tumor load at metastatic
             sites and/or symptomatic metastatic disease

          -  Cohort II: Chance of secondary resection with curative intent defined and reviewed by
             expert panel

          -  Adult patients (≥ 18 years of age)

          -  RAS wild-type tested in

               -  KRAS exon 2 (codons 12/13)

               -  KRAS exon 3 (codons 59/61)

               -  KRAS exon 4 (codons 117/146)

               -  NRAS exon 2 (codons 12/13)

               -  NRAS exon 3 (codons 59/61)

               -  NRAS exon 4 (codons 117/146) assessed by an institution participating in and
                  certified by the specific working group of the Deutsche Gesellschaft für
                  Pathologie)

          -  At least one measurable lesion according to RECIST measured within 3 weeks prior to
             registration

          -  No previous chemotherapy for metastatic disease (adjuvant chemotherapy for
             non-metastatic disease is allowed if terminated more than 6 months ago)

          -  Performance status ECOG 0-1

          -  Male and female subjects &gt; 18 years of age

          -  Adequate haematological, hepatic, renal and metabolic function parameters:

        Leukocytes &gt; 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hb &gt; 9g/dl (may be
        transfused or treated with erythropoietin to maintain or exceed this level)Creatinine
        clearance ≥ 50 ml/min or serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x
        upper limit of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver
        metastases, or ≤ 5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper
        limit of normal Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal (may be
        substituted to maintain or exceed this level)

          -  Negative pregnancy test and willingness to use highly effective methods of
             contraception (per institutional standard) during treatment and for 6 months (male or
             female) after the end of treatment (adequate: oral contraceptives, intrauterine device
             or barrier method in conjunction with spermicidal jelly).

          -  Before subject registration, written informed consent must be given according to
             ICH-GCP, and national/local regulations.

        Exclusion Criteria:

          -  Past or current history of malignancies except for the indication under this study and
             curatively treated:

          -  Basal and squamous cell carcinoma of the skin

          -  In-situ carcinoma of the cervix

          -  Other malignant disease without recurrence after at least 5 years of follow-up

          -  Clinically significant cardiovascular disease in (incl. myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) ≤ 6 months before enrolment.

          -  Clinically relevant interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis
             or evidence of interstitial lung disease on baseline chest CT scan.

          -  History of evidence upon physical examination of CNS disease unless adequately treated
             (e.g. primary brain tumour, seizure not controlled with standard medical therapy,
             brain metastases or history of stroke).

          -  Pre-existing neuropathy &gt; grade 1 (NCI CTCAE), except for loss of tendon reflex

          -  Allogeneic transplantation requiring immunosuppressive therapy.

          -  Severe non-healing wounds, ulcers or bone fractions.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Patients not receiving therapeutic anticoagulation must have an INR &lt; 1,5 ULN and aPTT
             &lt; 1,5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is
             allowed as long as the INR or aPTT is within therapeutic limits (according to the
             medical standard in the institution) and the patient has been on a stable dose for
             anticoagulants for at least two weeks at the time of randomisation.

          -  Concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or
             analogue compounds).

          -  Major surgical procedure, open biopsy, nor significant traumatic injury within 28 days
             prior to study treatment start, or anticipation of the need for major surgical
             procedure during the course of the study except for surgery for colorectal cancer with
             curative intent and central venous line placement for chemotherapy administration.

          -  Pregnancy or breastfeeding women.

          -  Subjects with known allergy to the study drugs or to any of its excipients.

          -  Known DPD deficiency.

          -  Current or recent (within the 28 days prior to starting study treatment) treatment of
             another investigational drug or participation in another investigational study.

          -  Known grade III/IV allergic reaction against monoclonal antibodies.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; those conditions
             should be discussed with the subject before registration in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Geißler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology and Gastroenterology, Academic Teaching Hospital Esslingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Geißler, MD, PhD</last_name>
    <phone>0049 711 3103</phone>
    <phone_ext>2451</phone_ext>
    <email>m.geissler@klinikum-esslingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ralph Keller</last_name>
    <email>Ralph.Keller@aio-studien-ggmbh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <state>Baden-Württemberg</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Geißler, Prof. Dr.</last_name>
      <phone>0049 - 711 - 31 03</phone>
      <phone_ext>24 51</phone_ext>
      <email>m.geissler@klinikum-esslingen.de</email>
    </contact>
    <investigator>
      <last_name>Michael Geißler, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heike Mönnich, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen Bauer, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sven Weßendorf, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carsten Schwänen, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken Heilbronn GmbH</name>
      <address>
        <city>Heilbronn</city>
        <state>Baden-Württemberg</state>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, Prof. Dr.</last_name>
      <phone>0049 - 7131 - 49 28</phone>
      <phone_ext>01</phone_ext>
      <email>uwe.martens@slk-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Uwe Martens, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefanie Gabat, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marlene Weiß, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Markus Lindauer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Josef Huber</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum</name>
      <address>
        <city>Lahr</city>
        <state>Baden-Württemberg</state>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Egger, Dr.</last_name>
      <phone>0049 - 07821 - 93</phone>
      <phone_ext>24 00</phone_ext>
      <email>Matthias.Egger@le.ortenau-klinikum.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Egger, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonhard Mohr, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Voelkel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <state>Baden-Württemberg</state>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Württemberg</state>
        <zip>68135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <state>Baden-Württemberg</state>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
      <phone>0049 - 71 71 - 701 13</phone>
      <phone_ext>02</phone_ext>
      <email>holger.hebart@Stauferklinikum.de</email>
    </contact>
    <investigator>
      <last_name>Holger Hebart, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Esslingen gGmbH Klinik Nürtingen</name>
      <address>
        <city>Nürtingen</city>
        <state>Baden-Württemberg</state>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis und Tagesklinik Onkologie Hämatologie Gastroenterologie Palliativmedizin Drs. Höring, Respondek, Schwinger, Thunert</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70190</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm Zentrum für Innere Medizin</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Ettrich, Dr.</last_name>
      <phone>0049 - 0731 - 500 - 445</phone>
      <phone_ext>08</phone_ext>
      <email>thomas.ettrich@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Ettrich, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Bayern</state>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leopoldina-Krankenhaus der Stadt Schweinfurth gGmbH</name>
      <address>
        <city>Schweinfurt</city>
        <state>Bayern</state>
        <zip>97422</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kanzler, PD Dr.</last_name>
      <phone>0049 - 09721 - 720 24</phone>
      <phone_ext>82</phone_ext>
      <email>akram@leopoldina.de</email>
    </contact>
    <investigator>
      <last_name>Stephan Kanzler, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Reinel, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Buwe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe-Universität Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lothar Bergmann, Prof. Dr.</last_name>
      <phone>0049 - 69 - 63 01</phone>
      <phone_ext>51 21</phone_ext>
      <email>L.Bergmann@em.uni-frankfurt.de</email>
    </contact>
    <investigator>
      <last_name>Lothar Bergmann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeska Möntenich, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luise Mauze, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg GmbH</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Riera Knorrenschild, Dr.</last_name>
      <phone>0049 - 6421 - 286</phone>
      <phone_ext>2784</phone_ext>
      <email>rierakno@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Jorge Riera Knorrenschild, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manela Jänike</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franziskus Hospital Niels-Stensen-Kliniken Klinik für Internistische Onkologie und Hämatologie</name>
      <address>
        <city>Georgsmarienhütte</city>
        <state>Niedersachsen</state>
        <zip>49124</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Atzpodien, Prof. Dr.</last_name>
      <phone>0049 541 502</phone>
      <phone_ext>24 60</phone_ext>
      <email>atzpodien@franziskus.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital Osnabrück Niels-Stensen-Kliniken Klinik für Innere Medizin</name>
      <address>
        <city>Osnabrück</city>
        <state>Niedersachsen</state>
        <zip>49074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincenz-Krankenhaus</name>
      <address>
        <city>Paderborn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH</name>
      <address>
        <city>Trier</city>
        <state>Rheinland-Pfalz</state>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael R. Clemens, Prof. Dr.</last_name>
      <phone>0049 - 651 - 947</phone>
      <phone_ext>23 77</phone_ext>
      <email>clemens@mutterhaus.de</email>
    </contact>
    <investigator>
      <last_name>Michael R. Clemens, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rolf Mahlberg, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Boris Meuter, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <state>Sachsen-Anhalt</state>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Büchner-Steudel, Dr.</last_name>
      <phone>0049 - 345 - 557</phone>
      <phone_ext>26 68</phone_ext>
      <email>petra.buechner-steudel@medizin.uni-halle.de</email>
    </contact>
    <investigator>
      <last_name>Petra Büchner-Steudel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philipp Thermann, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Stein, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sonja Hiemer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>7740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Lindig, Dr. med.</last_name>
      <phone>0049 3641 - 9 32</phone>
      <phone_ext>45 86</phone_ext>
      <email>udo.lindig@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Udo Lindig, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars-Olof Mügge, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekkehard Eigendorff, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Pesters</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>AIO-Homepage</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

